Authors:

C Beltran Herrera¹ , V Suberviola Sanchez-Caballero¹ , S Briongos¹ , M Sarrion¹ , A Sanchez¹ , C Cortina¹ , A Estevez¹ , ML Giganto¹ , I Ponz¹ , D Vaqueriza¹ , M Dominguez¹ , E Gomez¹ , S Jimenez¹ , L Mora¹ , R Munoz¹ , ¹University Hospital Infanta Leonor - Madrid - Spain ,

Citation:

Introduction Sacubitril-valsartan (ARNI) has demonstrated to improve functional class (FC) by NYHA in patients (pts) with heart failure (HF) compared to ACEI with no higher complications rate. Our objective is to describe FC and real-life complications in pts treated with ARNI .Methods We  analyzed 63 pts, we evaluated FC by NYHA and complications (hypotension, impaired renal function and hyperkalemia) 3 and 6 months after ARNI. HF decompensations and drug withdrawals were evaluated after 6 months. Results:ARNI improves FC by NYHA at 3 and 6 months. There is no hypotension, impaired renal function or significant hyperkalemia at 3 and 6 months. 31.7% had history of HF in the 12 months before ARNI.  At 6 months there were only 5 HF, 2 with severe anemia as a trigger, 3 required admission and 2 were resolved on an outpatient basis. 2 drug withdrawals due to symptomatic hypotension and impaired renal function (Cr> 2.5 mg / dl) Conclusions:ARNI improves FC by NYHA without significant complications.There were a very small number of decompensations and drug withdrawals at 6 months.